Modern and new drug development is a team sport

Our drug development teams have collaborated with our partners on well over 250 programs, across all stages of drug development life cycle and in every therapeutic area from oncology to rare diseases.

Acting as your dedicated stewards, our best-practice, quantitative systems and integrated approach delivers significant time and cost savings while accelerating regulatory and commercial success. From clinical pharmacology to pharmacometrics to regulatory submission and strategy and market access, we have 650+ leading experts throughout the world who are dedicated to achieving your goals. Build your drug development dream team with Certara.

Contact Certara

How we help our clients

Go to Clinical Pharmacology
Clinical Pharmacology

Our clinical pharmacology expertise is critical for optimizing safety and efficacy in drug development. Clinical pharmacology compromises more than 50% of a drug label.

Go to Clinical Pharmacology
Go to Strategy
New Drug Development and Regulatory Submissions

With our proven quantitative systems and integrated approach, we help to navigate the increasingly complex landscape of drug development to maximize your probability of success.

Go to Strategy
Go to MBMA
Model-based Meta Analysis (MBMA)

MBMA is a quantitative framework that uses PK/PD and statistical modeling to leverage external clinical trial efficacy, tolerability, and safety data to inform drug development decisions.

Go to MBMA
Go to Pharmacometrics

Pharmacometrics uses mathematical and statistical models to quantify drug, disease, and trial information to help address critical drug development decisions.

Go to Pharmacometrics

Go to QSP
Quantitative Systems Pharmacology (QSP)

Improve R&D productivity with QSP models, which predict how drugs modify cellular networks in space and time and how they impact and are impacted by human pathophysiology.

Go to QSP
Go to QSTS
Quantitative Systems Safety and Toxicology

QSTS helps to characterize adverse drug reactions by describing modes of action as adverse outcomes pathways and perturbed networks versus conventional empirical end points and animal-based testing.

Go to QSTS
Go to Simcyp PBPK Modeling
Simcyp Physiologically-based Pharmacokinetic (PBPK) Modeling

Our bespoke and leading PBPK modeling and simulation (M&S) consulting services help answer a range of questions without having to resort to a clinical study.

Go to Simcyp PBPK Modeling
Go to VBE
Virtual Bioequivalence (VBE)

Our Simcyp virtual bioequivalence services helped to achieve the first and only application where a complex generic was approved by the FDA without the need for a comparative clinical endpoint study.

Go to VBE
Creating unquestionable value for our partners is our #1 priority

Leveraging our best-in-class capabilities in modeling & simulation, regulatory science, and market access, we work alongside your team to inform critical decisions and set you up for regulatory and commercial success.

Agility, communication, quality, and trust are paramount to the success of our partnerships.  Together with you, we are one, integrated and cohesive team that anticipates risks, creates a robust strategy, and delivers with seamless implementation.

Contact us
Your first choice partner

Why do global pharmaceutical companies, biotechnology startups, and venture capital and private equity firms alike choose Certara?

  • Our quantitative-driven approach.  Using modeling and simulation across the entire drug development life cycle, we help to de-risk your program, increase confidence in critical decisions, and help you reach your goals, smarter and faster
  • Our people.  We have the most experienced (and largest) team of experts with clinical pharmacologists, pharmacometricians, and regulatory scientists and writers, that is dedicated to achieve your success
  • Our proven track record.  We have a library of case studies on our successful collaborations in oncology, rare diseases, infectious diseases, neurodegenerative diseases, and more.
Start a conversation
Our experts
Patrick Smith, PharmD Senior Vice President, Integrated Drug Development, Strategy

With over 20 years of global drug development experience, Patrick works across all phases of drug development life cycle with particular expertise in infectious diseases, oncology, and inflammation as well as novel early development program design and applying modeling and simulation to solve critical development problems. Patrick has over 125 peer reviewed publications, in journals including NEJM and Lancet.

Fran Brown, PhD Senior Vice President, Integrated Drug Development

Fran has over 25 years of experience with strategic and operational global drug development from early discovery to filing and post-marketing.  She possesses a broad knowledge of strategic drug discovery and development, with a special focus on development strategy and the application of model-informed drug development (MIDD).

Rik de Greef, MSc Senior Vice President, Integrated Drug Development

Rik’s key interests are in the integration of model-based components with overall clinical pharmacology and clinical development deliverables throughout the development trajectory. He enjoys combining his analytical skills and creativity in designing efficient drug development strategies that address the right questions at the right time.

How can we help you?

Contact us today to discuss how we can accelerate your program.

Back to top